Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16555331 | 0.85 | CD274 (1.00) | CD274PDCD1 | |
| SCHEMBL16555270 | 0.85 | CD274 (1.00) | CD274PDCD1 | |
| SCHEMBL16555293 | 0.83 | CD274 (1.00) | CD274PDCD1 | |
| SCHEMBL16555074 | 0.83 | CD274 (1.00) | CD274PDCD1 | |
| SCHEMBL16554586 | 0.82 | CD274 (1.00) | CD274PDCD1 | |
| SCHEMBL17889703 | 0.81 | CD274 (1.00) | CD274PDCD1 | |
| SCHEMBL16555035 | 0.80 | CD274 (1.00) | CD274PDCD1 | |
| SCHEMBL16555132 | 0.80 | CD274 (1.00) | CD274 | |
| SCHEMBL16555112 | 0.80 | CD274 (1.00) | CD274 | |
| SCHEMBL16554980 | 0.79 | CD274 (1.00) | CD274PDCD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9872852-B2 | Compounds useful as immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-23 | — | — | US | disclosed |
| US-20160194307-A1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2016-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194307-A1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | CD74, HAVCR2, CD4 | CD274 121/4885PDCD1 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.